leisure time -WSS

leisure time

author：leisure time 2025-09-27 10:00:20 - browse：645

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Johnson & Johnson sues to stop Medicare negotiation

WSS

Medicare’s new pay boost for primary care is angering specialists

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Twill hunts for pharma partner to market its depression app

What is STAT's opinion section for?

Flagship, Pfizer team up in deal worth up to $7 billion

What is STAT's opinion section for?

leisure time

leisure time

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What we know about the American soldier detained in North Korea

Continuity nursing helped my family in our darkest PICU moments

First transplant of an entire human eye performed

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

15 die by electrocution after transformer explodes in northern India

The cancer drug shortage isn’t new — and neither are the solutions

Publishing genetic code of viruses could cause disaster

entertainment

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

Ventyx halts psoriasis drug development after lackluster trial results

Healthy food access boosts outcomes in two studies

Healthy food access boosts outcomes in two studies

Ohio still needs to do more to protect the right to abortion

hotspot

focus

hotspot

explore